{"doi":"10.1080/13543776.2024.2379924","title":"Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)","abstract":null,"journal":"Expert Opinion on Therapeutic Patents","year":2024,"id":683477,"datarank":0.37273599746820013,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.0,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":364541,"name":"Ru Zhang","orcid":"0000-0001-8744-4525","position":1,"is_corresponding":false},{"id":1785455,"name":"Jianyu Nie","orcid":null,"position":2,"is_corresponding":false},{"id":1785456,"name":"Mingxing Zhu","orcid":null,"position":3,"is_corresponding":false},{"id":1785458,"name":"Zhouling Xie","orcid":null,"position":4,"is_corresponding":false},{"id":501632,"name":"Chenzhong Liao","orcid":"0000-0001-7080-1768","position":5,"is_corresponding":false},{"id":474706,"name":"Qin Wang","orcid":"0000-0002-8384-7703","position":6,"is_corresponding":false},{"id":1785452,"name":"Shirong Bian","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)","abstract":"INTRODUCTION: Polo-like kinases (PLKs) have five isoforms, all of which play crucial roles in cell cycle and cell proliferation, offering opportunities for drug design and treatment of cancers and other related diseases. Notably, PLK1 and PLK4 have been extensively investigated as cancer drug targets. One distinctive feature of PLKs is the presence of a unique polo-box domain (PBD), which regulates kinase activity and subcellular localization. This provides possibilities for specifically targeting PLKs. AREA COVERED: This article provides an overview of the roles of PLKs in various cancers and related diseases, as well as the drug development involving PLKs, with a particular focus on PLK1 and PLK4. It summarizes the PLK1 and PLK4 inhibitors that have been disclosed in patents or literature (from 2018 - present), which were sourced from SciFinder and WIPO database. EXPERT OPINION: After two decades of drug development on PLKs, several drugs progressed into clinical trials for the treatment of many cancers; however, none of them has been approved yet. Further elucidating the mechanisms of PLKs and identifying and developing highly selective ATP-competitive inhibitors, highly potent drug-like PBD inhibitors, degraders, etc. may provide new opportunities for cancer therapy and the treatment for several nononcologic diseases. PLKs inhibition-based combination therapies can be another helpful strategy.","is_dataset_classified":null,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38994687","pmcid":null,"openalex_id":"https://openalex.org/W4400588577","authors":[],"funders":[{"funder_name":"Anhui Provincial Natural Science Foundation","grant_id":"2308085MH310","title":null},{"funder_name":"Anhui Provincial Key Research and Development Project","grant_id":"2022i01020004","title":null}],"total_grants":2,"fwci":2.4908,"citation_percentile":0.88952729,"influential_citations":0,"citation_trend":[{"year":2025,"count":9},{"year":2026,"count":2}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://www.tandfonline.com/doi/pdf/10.1080/13543776.2024.2379924","host_type":"publisher"},{"url":"https://doi.org/10.1080/13543776.2024.2379924","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38994687","host_type":"repository"}],"fields_of_study":["Microtubule and mitosis dynamics","Lung Cancer Treatments and Mutations","14-3-3 protein interactions"],"mesh_terms":["Drug Development","Polo-Like Kinase 1","Animals","Antineoplastic Agents","Humans","Neoplasms","Patents as Topic","Proto-Oncogene Proteins","Drug Design","Protein Serine-Threonine Kinases","Cell Cycle Proteins","Protein Kinase Inhibitors","Cell Proliferation","Molecular Targeted Therapy"],"keywords":["PLK1","Polo-like kinase","Kinase","Drug development","Cell biology","Biology","Protein kinase domain","Cell cycle","Computational biology","Drug","Cell","Biochemistry","Pharmacology","Gene"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-18T11:15:41.274655Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}